Follistatin-like 1 promotes proliferation of matured human hypoxic iPSC-cardiomyocytes and is secreted by cardiac fibroblasts

Marijn C. Peters,1 Sofia Di Martino,1 Thomas Boelens,1 Jiabin Qin,1 Alain van Mil,1 Pieter A. Doevendans,1 Steven A.J. Chamuleau,1,2 Joost P.G. Sluijter,1,3 and Klaus Neef1,3

1Department of Cardiology, Laboratory of Experimental Cardiology, Regenerative Medicine Centre Utrecht, University Medical Centre Utrecht, University Utrecht, 3584 CX Utrecht, the Netherlands; 2Department of Cardiology, Amsterdam Medical Centre, 1105 AZ Amsterdam, the Netherlands

The human heart has limited regenerative capacity. Therefore, patients often progress to heart failure after ischemic injury, despite advances in reperfusion therapies generally decreasing mortality. Depending on its glycosylation state, Follistatin-like 1 (FSTL1) has been shown to increase cardiomyocyte (CM) proliferation, decrease CM apoptosis, and prevent cardiac rupture in animal models of ischemic heart disease. To explore its therapeutic potential, we used a human in vitro model of cardiac ischemic injury with human induced pluripotent stem cell-derived CMs (iPSC-CMs) and assessed regenerative effects of two differently glycosylated variants of human FSTL1. Furthermore, we investigated the FSTL1-mediated interplay between human cardiac fibroblasts (cFBs) and iPSC-CMs in hypoxia. Both FSTL1 variants increased viability, while only hypo-glycosylated FSTL1 increased CM proliferation post-hypoxia. Human fetal cardiac fibroblasts (fCFBs) expressed and secreted FSTL1 under normoxic conditions, while FSTL1 secretion increased by iPSC-cFBs upon hypoxia but decreased in iPSC-CMs. Co-culture of iPSC-CMs and cFBs increased FSTL1 secretion compared with cFB mono-culture. Taken together, we confirm that FSTL1 induces iPSC-CM proliferation in a human cardiac in vitro hypoxia damage model. Furthermore, we show hypoxia-related FSTL1 secretion by human cFBs and indications for FSTL1-mediated intercellular communication between cardiac cell types in response to hypoxic conditions.

INTRODUCTION

The human heart has limited regenerative capacity. Therefore, patients often progress to heart failure after ischemic injury, despite advances in reperfusion therapies generally decreasing mortality. In contrast to the adult human heart, neonatal vertebrate and invertebrate hearts can substantially regenerate from injury or disease via induced proliferation of cardiomyocytes (CMs) in situ.1,2 As damaged adult CMs in the human heart show up-regulation of genes involved in heart development and invertebrate heart regeneration, a rudimentary cardiac regeneration mechanism seems to exist, yet it is inefficient to cope with massive CM damage or loss (e.g., inflicted by ischemic insult from myocardial infarction).3–5 Thus, stimulation of the CM cell cycle to potentially re-establish regenerative capacity in the adult human heart has become a key focus in the field of advanced cardiac therapies. Induction of CM proliferation in regenerating hearts has been linked to paracrine signaling, often attributed to secretion from the epicardium.6–10 Furthermore, efficient cardiac regeneration has been shown to be accompanied by revascularization induced by epicardial derived endothelial and smooth muscle cells.10,11 These cellular responses to tissue damage rely on intercellular communication via soluble paracrine factors12 and the close proximity of endothelial cells, cardiac fibroblasts (cFBs), and CMs.17,18 Changes in the cellular composition after an ischemic insult (i.e., increased frequency of cFBs and decreased frequency of CMs and endothelial cells) alter paracrine signaling and cross-talk between cardiac cells and thus effects damage response.16,19 The epicardium has been identified to be instrumental in mediating cardiac regeneration initially in the zebrafish heart, and epicardially secreted glycoprotein Follistatin-like-1 (FSTL1) has been confirmed to act as myogenic cardiokine in murine and porcine cardiac injury models.20 Furthermore, cardioprotective and angiogenic effects of FSTL1 have been reported.21–28 FSTL1 is a 308 amino acid glycoprotein of the SPARC protein family, with three N-glycosylation sites,27,29,31 with one (N180) being critically linked to the role of FSTL1 in cardiac regeneration.31 Additionally, an increase in secretion of FSTL1 with higher molecular weight, likely due to protein glycosylation, could be observed in mouse serum and myocardium after myocardial infarction.26,28 All this strongly suggests that regulation of FSTL1 expression and glycosylation after myocardial infarction could guide approaches on exploiting its regenerative potential for the heart. Besides its role in CM renewal, the expression

Received 13 August 2021; accepted 19 February 2022; https://doi.org/10.1016/j.omtm.2022.02.005.

These authors contributed equally

Correspondence: Klaus Neef, Department of Cardiology, Laboratory of Experimental Cardiology, Regenerative Medicine Centre Utrecht, University Medical Centre Utrecht, University Utrecht, 3584 CX Utrecht, the Netherlands.

E-mail: k.neef@umcutrecht.nl
of FSTL1 by cFBs in the infarct area was found to be essential to prevent cardiac rupture.32,33

As indicated, so far animal studies have shed some light on FSTL1 as a potential therapeutic agent to induce cardiac regeneration by stimulating both CM proliferation, protection from apoptosis, revascularization, and stabilizing the infarct scar. However, these findings have yet to be confirmed in a human setting. The development of CMs derived from human induced pluripotent stem cells (iPSC-CMs) has become a new promising way to model the complex cellular physiology of human cardiac cells, while taking into account the usually relatively immature phenotype of iPSC-CMs.34 Using methods to stimulate metabolic maturation of iPSC-CMs and stimulate oxidative phosphorylation-based energy metabolism35 to improve their susceptibility to hypoxic damage and thus their applicability to model ischemic heart disease.

In this study, we sought to assess the cardiac regenerative capacity of FSTL1, taking into account the glycosylation state, using a human iPSC-CM-based in vitro hypoxia model, and exploring a potential role of cFBs.

RESULTS

Hypo- and hyperglycosylated FSTL1 variants exert cardioprotective effects

We analyzed cardioprotective effects of FSTL1 and the effect of FSTL1 glycosylation by treating CMs with bacterially produced human recombinant FSTL1 (low-glycosylated [glylow-FSTL1]) or mammalian produced human recombinant FSTL1 (high-glycosylated [glyhigh-FSTL1]) at the onset of 24 h hypoxia (Figure 1A). The increased molecular weight of glyhigh-FSTL1 was confirmed using western blot (50 vs. 37 kDa [glylow-FSTL1]) (Figure 1B). Flow cytometric analysis showed a significant increase in viability after treatment with either

![Figure 1. FSTL1 increases survival of hypoxic matured iPSC cardiomyocytes](image-url)

(A) Schematic representation of experimental setup. (B) Western blot analysis of glylow-FSTL1 and glyhigh-FSTL1. (C) Flow cytometry analysis of live dead staining. (D) Quantification of (C). (E) Microscopic images of TUNEL-stained iPSC-CM. (F) Quantification of (E) (n = 3 biological replicates). Data was analyzed using one-way ANOVA and Dunnett multiple-comparisons test. *p < 0.05, **p < 0.01, and ***p < 0.001. Scale bar: 200 μm. Data are presented as mean ± SEM. To see this figure in color, go online.
**A**

Nutrients MM Starvation

- 21% O2
- 1% O2

**B**

Relative gene expression (normalized to TBP)

|       | Control | gly<sup>−/−</sup>-Fasl1 | gly<sup>−/−</sup>-Fasl1 |
|-------|---------|-------------------------|-------------------------|
| KIF7  | *       | *                       | *                       |
| CCNB2 |         |                         |                         |

**C**

K<sup>577</sup> (4G10) ACTN1 (4G18)

**D**

K<sup>577</sup> cardiomyocytes (normalized to control)

**E**

Healthy | Hypoxia

**F**

K<sup>577</sup> Cardiomyocytes (%)

|       | Control | gly<sup>−/−</sup>-Fasl1 | gly<sup>−/−</sup>-Fasl1 |
|-------|---------|-------------------------|-------------------------|
|       | *       | *                       | *                       |

**G**

Hypoxia

**H**

Aurora b ACTN1 DAPI

**I**

Hypoxia

**J**

pH<sub>3</sub> ACTN1 DAPI

**K**

Healthy | Hypoxia

**L**

EdU ACTN1 DAPI

(legend on next page)
glycosylation variant compared with control (from 70% ± 3.6% [control] to 81% ± 2.3% [glylow-FSTL1] or 79.4% ± 1.9% [glyhigh-FSTL1], p < 0.05; Figures 1C and 1D). Furthermore, both glycosylation variants of FSTL1 decreased the number of TUNEL+ iPSC-CMs (from 37.6 ± 3.5 [control] to 22.6 ± 1.2 [glylow-FSTL1] or 24.9 ± 1.5 [glyhigh-FSTL1], p < 0.01; Figures 1E and 1F).

**Hypo-glycosylated FSTL1 increases proliferation of hypoxic mature iPSC-CMs**

To determine whether FSTL1 could promote proliferation in metabolically maturated iPSC-CMs, we exposed the cells to FSTL1 at the onset of 24 h hypoxia (Figure 2A). Glylow-FSTL1 treatment prior to 24 h hypoxia increased the mRNA expression of proliferation marker Ki67 compared with control and G1/S cell cycle marker CYCLIN D2 compared with control (Figure 2B). Expression of proliferation marker Ki67 was increased after glylow-FSTL1 treatment, as confirmed by flow cytometry (Figures 2C and 2D) and immunocytochemistry (Figures 2E and 2F), while treatment with glyhigh-FSTL1 did not increase Ki67 expression (Figures 2D and S1). Similarly, only glylow-FSTL1 treatment increased expression of the cytokinesis marker Aurora B kinase (from 1.76% ± 0.18% [control] to 3.8% ± 0.61% [glylow-FSTL1]), p < 0.05; Figures 2G and 2H) and the mitotic marker pH3 (from 1.12% ± 0.33% [control] to 4.13% ± 0.57% [glylow-FSTL1], p < 0.01; Figures 2I and 2J). To further validate if FSTL1 increases proliferation, iPSC-CMs were incubated with 5-ethyl-20-deoxyuridine (EdU) at the moment of FSTL1 administration, at the onset of 24 h hypoxia, to analyze DNA synthesis. Glylow-FSTL1 dose-dependently increased EdU incorporation in hypoxic CMs, while glyhigh-FSTL1 did not (6.13 ± 1.6 [0 ng/mL glylow-FSTL1], 19.0% ± 1.91% [50 ng/mL glylow-FSTL1], and 1.69% ± 0.43% [50 ng/mL glyhigh-FSTL1]; Figures 2K and 2L).

We have shown that glylow-FSTL1 induced proliferation of iPSC-CMs when supplemented at the start of hypoxia. To assess potential FSTL1-related effects on already damaged cells, we supplemented iPSC-CMs with FSTL1 24 h after hypoxia and analyzed for expression of proliferation markers after another 48 h of normoxic conditions (Figure 3A). Again, glylow-FSTL1 induced increased expression of Ki67 (from 0.4% ± 0.13% [control] to 1.84% ± 0.61% [glylow-FSTL1], p < 0.05), pH3 (from 0.29% ± 0.14% [control] to 1.89% ± 0.44% [glylow-FSTL1]), p < 0.01, and Aurora B kinase (from 1.0% ± 0.38% [control] to 6.2% ± 2.2% [glylow-FSTL1]), p < 0.05 (Figures 3B–3G) compared with control. Furthermore, incorporation of EdU was significantly increased after treatment with glylow-FSTL1 compared with control (9.11 ± 3.3 [control] and 23.0% ± 2.84% [50 ng/mL glylow-FSTL1]; Figures 3H and 3I).

RNA expression profile of FSTL1-treated hypoxic mature iPSC-CMs

To assess the effect of the FSTL1 glycosylation variants on gene expression, we compared RNA sequencing (RNA-seq) transcriptional profiles of iPSC-CM after hypoxia and pre-treatment with glylow-FSTL1, glyhigh-FSTL1, and sham-treated controls (n = 5). Using DESeq2 analysis and an adjusted p value threshold of 0.1, we identified 2,405 differentially regulated genes with 1,981 up-regulated and 424 down-regulated genes in glylow-FSTL1-treated hypoxic iPSC-CMs compared with control hypoxic iPSC-CMs (Figure 4A and 4B). Principal component (PC) analysis showed scattering of the samples according to the largest variance between samples, indicating clustering on the basis of iPSC-CM cell line and experimental batch. No significantly differentially expressed genes could be found in glyhigh-FSTL1-treated hypoxic iPSC-CMs compared with control hypoxic iPSC-CMs (Figure S2). Gene Ontology enrichment analysis indicated that biological processes highly up-regulated in glylow-FSTL1-treated hypoxic iPSC-CMs were linked to cell proliferation (e.g., nuclear division, mitosis, cell junction organization), cardiac development and function, and cellular response to oxidative stress (Figure 4C). Analysis of specifically up-regulated genes after glylow-FSTL1 treatment showed up-regulation of cell cycle genes, DNA repair genes, and antioxidant genes, while treatment with glyhigh-FSTL1 did not induce similar up-regulation (Figure 4D). Among down-regulated biological processes after glylow-FSTL1 treatment were pathways linked to G protein-coupled receptor and immune system activation (Figure 4E). Differential expression analysis between control, glylow-FSTL1, and glyhigh-FSTL1 indicated significantly increased mRNA expression of cell cycle genes, DNA damage repair genes, and antioxidants after glylow-FSTL1 treatment. All together, we have shown that only glylow-FSTL1 specifically activates cell proliferation and reparative response to oxidative stress.

Human cardiac fibroblasts secrete FSTL1, and co-culture with cardiomyocytes increases FSTL1 secretion

We have shown that exposure to glylow-FSTL1 can induce protective effects and proliferation in hypoxia-challenged iPSC-CMs. As cFBs are present in the human heart at a similar frequency as cardiomyocytes and therefore could be a source of paracrine FSTL1, we assessed FSTL1 expression of cFBs in fcFBs and iPSC derived cFBs (IPSC-cFBs; Figure 5A) in response to hypoxia. FcFBs and IPSC-cFBs expressed cell type-defining markers vimentin and collagen 1 (Figures 5B and 5C). qRT-PCR analysis for FSTL1 revealed all three cell lines, iPSC-CMs, and both cFBs, expressed at similar levels at normoxic conditions (Figure 5D). Change to hypoxic conditions showed no significant changes in mRNA expression in fcFBs, iPSC-cFBs, or iPSC-CMs. Analysis of intracellular (i.e., not secreted) FSTL1 protein

---

**Figure 2.** Glylow-FSTL1 treatment induces proliferation in normoxic and hypoxic mature iPSC-CMs.

(A) Schematic representation of experimental setup. (B) mRNA expression of cell cycle genes Ki67 and CNND2 (CYCLIN D2) normalized to TATA binding protein (TBP) expression. (C and D) Flow cytometry analysis of Ki67-positive iPSC-CMs (C) and quantification (D). (E–J) Representative images and quantification of Ki67 (E and F), pH3 (G and H), and Aurora B kinase (I and J). (K and L) Microscopic images of EdU, ACTN1 staining (K), and quantification (L). Arrowheads indicate EdU + iPSC-CMs. n = 3 for staining and n = 6 for flow cytometry (both biological replicates). Data were analyzed using one-way ANOVA and Dunnett multiple-comparisons test. *p < 0.05, **p < 0.01, and ***p < 0.001. Scale bar: 200 μm. Data are presented as mean ± SEM. To see this figure in color, go online.
expression showed that fcFBs and iPSC-cFBs express FSTL1 protein at similar levels. Interestingly, fcFBs expressed FSTL1 of both molecular weights (~37 and ~50 kDa), presumably representing both glycosylation variants (Figures 5E and 5F), while iPSC-cFBs expressed only the lower molecular weight variant, with similar gel migration as the non-glycosylated FSTL1 (gly<sub>low</sub>) (Figures 5G and 5H). Hypoxic conditions decreased expression of both variants in fcFBs (Figures 5E and 5F), while no significant changes were observed in iPSC-cFBs (Figures 5G and 5H). Preliminary analysis of FSTL1 expression in iPSC-CMs showed predominant expression of high-molecular weight FSTL1 and a trend toward decreased expression over time of hypoxia exposure (Figures 5I and 5J).

We have shown that both fcFBs and iPSC-cFBs express FSTL1, and expression is decreased in prolonged hypoxia. We next aimed to determine the secretion of FSTL1 by iPSC-cFBs and iPSC-CMs and if secretion is changed by hypoxia. Media concentrations of secreted FSTL1 were determined with the Luminex multiplex detection system at normoxic baseline and after 4 or 24 h of hypoxia. In normoxic conditions, iPSC-CMs and iPSC-cFBs secreted similar levels of FSTL1 (6,327 ± 170.4 pg/mL [iPSC-cFBs] and 6,229 ± 163.1 pg/mL [iPSC-CMs]; Figure 6A). Interestingly, although hypoxia did not significantly increase internal FSTL1 protein levels in iPSC-cFBs, media FSTL1 levels increased in hypoxia (from 6,327 ± 170.4 pg/mL [24 h, 21% O<sub>2</sub>] to 8,582 ± 376.8 pg/mL [24 h, 1% O<sub>2</sub>; p < 0.01]). In iPSC-CMs, hypoxia decreased FSTL1 protein secretion (from 6,229 ± 163.1 pg/mL [24 h, 21% O<sub>2</sub>] to 5,250 ± 102.5 pg/mL [24 h, 1% O<sub>2</sub>; p < 0.01] (Figure 6A).

To determine whether FSTL1 secretion changes when both cell types are present, iPSC-CMs and iPSC-cFBs from the same cell line were co-cultured at 80%:20% iPSC-CM/iPSC-cFB and 20%:80% iPSC-CM/iPSC-cFB. Interestingly, although co-culture conditions showed decreased FSTL1 secretion after short-term hypoxia, compared with iPSC-CM mono-culture, exposure to hypoxic conditions, FSTL1 secretion was still higher than in mono-cultures under the same conditions (with the exception of 80%:20% co-culture for short-term hypoxia, compared with iPSC-CM mono-culture).

Altogether, we reported marked differences in FSTL1 secretion between cell types, during co-culture of CMs and FBs and upon change from normoxic to long- and short-term hypoxia (Figures 6E and S3), pointing to the in vivo role of FSTL1 in CM-FB communication during normoxia and hypoxia, as present in ischemic heart disease. A shift in FSTL1 secretion from short- to long-term hypoxia could play a role in the post-hypoxic cardiac response.

**DISCUSSION**

In this study, we report that FSTL1 can protect human iPSC-CMs from hypoxia-induced cell death independent of protein glycosylation, and that we found that non-glycosylated FSTL1 stimulates the proliferation of metabolically mature human CMs when administered either before or after injury. Furthermore, we report that both human iPSC-CMs and iPSC-cFBs secrete FSTL1, which upon change to hypoxic conditions decreases for iPSC-CMs but increases for iPSC-cFBs. Previously, iPSC-CMs have been reported to have an immature metabolic phenotype, relying mainly on anaerobic glycolysis for ATP production instead of oxidative phosphorylation, as seen in adult CMs. The metabolic demand affects the ability to reflect the phenotype of adult CMs during ischemic injury, as in the myocardium the absence of oxygen and nutrients induces a shift toward glycolytic metabolism. In this study, we used maturation media to shift the metabolism of the iPSC-CMs toward oxidative phosphorylation and therefore increase susceptibility to hypoxic conditions. As these metabolically matured human iPSC-CMs with very limited basal cell cycle activity could be stimulated by FSTL1 to proliferate upon exposure to hypoxic conditions, activation of CM proliferation in the adult human heart, seems possible but obviously needs further evaluation along the translational axis.

Previous studies have attempted to stimulate CM proliferation by targeting YAP1-Hippo, ErbB2, and Notch signaling, but so far, clinical translation has failed. The commonly used proliferation marker Ki67 has been found to also be expressed in non-proliferating cells when there is overexpression of cell damage markers P53 and P21, which could bias reported effects of regenerative factors. However, the reduced regenerative effect in translational studies could also be related to differences between animal models and the human heart and delivery issues.

Furthermore, with regenerative approaches the focus often is on the stimulation of CM proliferation, while restoration of vascularization...
and preventing extensive fibrosis are also required to enable cardiac regeneration. In light of this, studying regenerative factors that can also stimulate angiogenesis and target fibroblast behavior and function in intercellular communication could be a promising approach. We report that FSTL1 can double or triple the expression of multiple proliferation markers in human CMs to similar percentages of EdU and pH3 expression as reported in previous animal studies and higher Aurora B kinase levels than in previous studies. This, together with previous reports of FSTL1-mediated increase cardiac vascularization and cardioprotection, makes it a promising candidate factor to target cardiac repair. Additionally, we report differential gene expression after glylow-FSTL1 treatment in which all biological processes of cell proliferation (nuclear division, G2/M progression, mitosis, anaphase) and the protective response to oxidative stress and reactive oxygen species are up-regulated. Furthermore, genes involved in cytolysis and immune cell activation were significantly

Figure 4. RNA expression profile of FSTL1-treated hypoxic iPSC-CMs

(A) Principal component analysis (PCA) plots of hypo-glycosylated FSTL1-treated hypoxic iPSC-CMs and control hypoxic iPSC-CMs showing the separation between the samples on the basis of the top differentially expressed genes using DESeq2. (B) MA density plot of up- and down-regulated genes in glylow-FSTL1-treated iPSC-CMs compared with control using DESeq2. The x axis shows mean values of normalized counts of all samples, and the y axis shows log2 fold change in expression. (C) Gene Ontology (GO) enrichment analysis of GO term biological processes showing the top up-regulated biological processes enriched after treatment with glylow-FSTL1 compared with control. (D) Heatmap of normalized reads of significantly up-regulated cell cycle, DNA repair, or antioxidant genes after glylow-FSTL1 treatment compared with control, analyzed using Limma-voom differential expression analysis. Fold change compared with control is shown. (E) Gene Ontology enrichment analysis of GO term biological processes showing the top down-regulated biological processes enriched after treatment with glylow-FSTL1 compared with control. To see this figure in color, go online.
Glycosylation has been linked to biological activity of FSTL1 in multiple contexts. It is important to include analysis of glycosylation of secreted proteins, as this could provide insights into the complex intercellular communication taking place. Future studies will be necessary to better understand the role of glycosylation in FSTL1 function.

The secretion of cardiokines plays important roles in intercellular communication during physiology and disease both by mediating paracrine cross-talk inside the heart and by facilitating communication with peripheral organs. The release of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) has been found to enable dynamic motion of the ventricular wall, while cardiokine IL-33 released by cFBs regulated CM hypertrophy via CM soluble protein ST2. Hypoxia-inducible cardiokine secretion has been reported in the murine heart, among which FSTL1 was identified as a cardioprotective cardiokine capable of preventing CM apoptosis. Cellular FSTL1 secretion by epicardial cells, CMs, and cFBs has been reported in previous studies. In murine ischemic hearts, expression of FSTL1 was found to be essential in preventing cardiac rupture when expressed by cFBs. Expression of non-glycosylated FSTL1 was found to be capable of stimulating immature CMs to proliferate. In the human heart, elevated FSTL1 plasma levels and CM FSTL1 secretion have been reported in patients with heart failure. As hypoxia impairs endoplasmic reticulum (ER) protein synthesis, protein secretion is decreased for most proteins. Maintained or increased protein secretion during ER stress suggests important functions for these proteins in the post-ischemic repair response. Potential mechanistic pathways of secreted FSTL1-mediated induction of cell survival and proliferation have been described, but further elucidation on (cardiac cell type) specific receptors and downstream targets is still required to fully understand the complex inter- and intracellular processes.

Our data demonstrate that hypoxic conditions induce an increase of FSTL1 secretion only from cardiac fibroblasts, while it decreases from iPSC-CMs. Furthermore, we found cFB cell line differences in FSTL1 expression, with fcFBs expressing both glycosylation variants, while iPSC-cFBs expressed only glylow-FSTL1. Intriguingly, FSTL1 expression in iPSC-CMs was shown to be exclusively glyhigh-FSTL1. It will be important to include analysis of glycosylation of secreted and thus paracrine-active FSTL1 in future studies to better understand this aspect of the complex intercellular communications taking place. Glycosylation has been linked before to biological activity of FSTL1 during differentiation. This is the first report of FSTL1 expression and secretion by human iPSC-cFBs and iPSC-CMs. We have shown that co-culture of both cell types increases FSTL1 secretion, indicating intercellular communication related to FSTL1. Interestingly, FSTL1 secretion from co-cultures under hypoxia was generally higher than from mono-cultures, while exposure to hypoxia mostly decreased FSTL1 secretion in iPSC-CM/iPSC-cFB co-cultures compared with normoxia. The complex nature of FSTL1 expression levels by iPSC-CMs and iPSC-cFBs in co-culture between hypoxic and normoxic conditions requires further investigation. Further elucidation of FSTL1 signaling between CMs and cFBs in the healthy and ischemic heart could provide insights into how we can tap into this intercellular communication to support cardiac repair. As we confirm that FSTL1 acts as a secreted, paracrine factor, clinical translation could be accomplished via various delivery routes to ensure effective local concentrations, for example, by applying an epicardial patch, drug-releasing carriers such as injectable gels, or implantable mini-pumps. Large animal models using clinically applicable methodology seem an appropriate means to further investigate the translational potential of FSTL1 for ischemic heart disease.

Figure 5. Normoxic and hypoxic human cardiac fibroblasts produce FSTL1
(A) Schematic representation of experimental setup. (B and C) Microscopic images of vimentin-1 and collagen 1 staining of human fetal cardiac fibroblasts (fcFBs) (B) and human iPSC-cFBs (C). (D) Endogenous FSTL1 mRNA expression levels normalized to TATA binding protein (TBP) levels. (E–J) FSTL1 protein expression levels of fcFBs (E and F), iPSC-cFBs (G and H), and iPSC-CMs (I and J) under normoxic and hypoxic conditions as determined using western blot. n = 3 (biological replicates). Data were analyzed using one-way ANOVA and Dunnett multiple-comparisons test. *p < 0.05, **p < 0.01, and ***p < 0.001. Scale bar: 200 μm. Data are presented as mean ± SEM. To see this figure in color, go online.
MATERIALS AND METHODS
Cell culture
Human iPSC lines were kindly provided by Joseph Wu (SCVI-273) and Tomo Saric (NP0141-31B), and isolation of peripheral blood mononuclear cells and reprogramming were performed as previously described. 70,71 iPSCs were grown in Essential 8 media (A1517001; Gibco) until they reached 90%–100% confluency. Differentiation to iPSC-CMs was initiated by changing media to RPMI 1640 (11875085; Thermo Fisher Scientific) and B27 minus insulin supplement (A1895601; Thermo Fisher Scientific) containing 7 μM CHIR99021 (S2924; Selleck Chemicals). After 3 days, canonical Wnt signaling was inhibited through the supplementation with

Figure 6. FSTL1 secretion is increased from iPSC-cFBs but decreased from iPSC-CMs in hypoxic conditions
(A) FSTL1 medium concentrations as determined using Luminex assay. (B and C) Microscopic images of collagen 1 and a-actinin staining of cardiomyocyte/fibroblast cocultures in normoxia (B) and hypoxia (C). (D) FSTL1 media concentrations in normoxia, short-term hypoxia, and long-term hypoxia as determined using Luminex assay. (E) Comparison of FSTL1 secretions of different cell types in normoxic and hypoxic conditions. Changes depict higher, equal, or lower expression of the cell types in the rows compared with the columns. n = 4 (biological replicates). Data were analyzed using one-way ANOVA and Dunnett multiple-comparisons test. *p < 0.05, **p < 0.01, and ***p < 0.001. Scale bar: 200 μm. Data presented as mean ± SEM. To see this figure in color, go online.
Wnt-C59 (5148; R&D Systems). At day 7, the media was changed to RPMI 1640 and B27 plus insulin supplement (17504001; Thermo Fisher Scientific), after which the iPSC-CMs were purified in RPMI 1640 with no glucose (11897920; Thermo Fisher Scientific) at day 9. At day 11 of differentiation, cells were re-plated in 10% KnockOut Serum Replacement (KOSR) (108280028; Thermo Fisher Scientific) RPMI/B27 plus insulin. After a second purification step, media was changed to RPMI/B27 plus insulin. At day 20, media was changed to maturation media, as previously described.72 Cells were matured in maturation media for 3 weeks before re-plating.

iPSC-cFBs were differentiated from iPSCs as previously described.72 In short, differentiation was started at 100% confluency by changing media to RPMI 1640 and B27 minus insulin supplement containing 16 µM CHIR99021. After 2 days, media was changed to CFBM media supplemented with 75 ng/mL bFGF (WiCell Research Institute). Media was changed every other day with CFBM media72 supplemented with 75 ng/mL bFGF before passaging with TrypLE Express (12604013; Gibco) to DMEM (11995065; Gibco)/10% fetal bovine serum (12103C; Sigma Aldrich)/1% B27 plus insulin media at day 20.

Human fetal tissue was obtained following parental permission using standard informed consent procedures, and f:FBs were isolated as previously described.73

**Hypoxia simulation**

Cells were exposed to 1% O2 in a hypoxia workstation (Baker Ruskinn InvivO2 1000) or <1% O2 in a BD GasPak EZ Pouch system for 4 or 24 h after 24 h glucose starvation.

**FSTL1 supplementation**

Recombinant human FSTL1 synthesized in *Escherichia coli* (glyhigh-FSTL1; Aviscera Bioscience) and in a mouse myeloma cell line (glylow-FSTL1; R&D Systems) were used.

Twenty-four hours prior to hypoxia or after hypoxia, cells were supplemented with FSTL1 (1–500 ng/mL) before measurement of EdU incorporation. Similarly, cells were supplemented with FSTL1 (100 ng/mL) for Ki67, PH3, Aurora B kinase immunofluorescence staining, RNA expression analysis, and flow cytometric analysis.

**Immunofluorescence**

Cells were fixed in 4% paraformaldehyde and permeabilized in 0.1% Triton X-100 before blocking in 10% normal goat serum/1% BSA (Millipore Sigma). Cells were incubated with primary antibodies (α-actinin [1:200; A7811; Sigma-Aldrich], cardiac troponin T [1:100; ab45932; Abcam], K67 (1:200; ab8330; Abcam), PHH3 [1:200; 9701; Cell Signaling Technology], and Aurora B kinase [1:100; ab2254; Abcam]) overnight, and detection was mediated by incubation with secondary antibodies (Alexa Fluor antibody conjugates; Thermo Fisher Scientific) for 1 h. DAPI was used as a nuclear marker. Mounting was performed using Fluoromount-G mounting medium (Thermo Fisher Scientific).

To determine cell loss via pathways involving DNA fragmentation, TUNEL assays (Roche) were performed according to the manufacturer’s instructions. *In vitro* proliferation after FSTL1 supplementation was assessed using Click-it EdU incorporation kit (Life Technologies). Imaging was performed using a confocal microscope (Leica SP8 X) and image analysis using ImageJ.

**RNA extraction and qPCR**

RNA was extracted from the cells with TriPure isolation reagent (Roche) and reverse-transcribed to cDNA using the qScript cDNA synthesis kit (QuantaBio). Expression of target genes was determined using Perfecta SYBR Green SuperMix (QuantaBio) and gene-specific primers. TATA box binding protein (TBP) mRNA expression was used as a housekeeping reference, and expression levels were normalized to control using the ΔΔCT quantification method.

**RNA sequencing**

After RNA extraction, RNA quality was determined using Qubit RNA HS Assay Kit (Thermo Fisher Scientific) and the Qubit fluorometer. The RNA library was prepared using the NEXTflex Rapid RNA-Seq Kit (Bio Scientific) and sequenced using CEL-seq (ILLUMINA) to determine RNA expression. The Galaxy environment74 was used to analyze differential expression between two groups with DESeq2 and Limma-voom between more than two groups. Pairwise comparison between groups were conducted by applying the Wald test of the negative binomial distribution to the log2 gene counts, and significance was determined using an adjusted p value < 0.05. Because of the sensitive nature of the human RNA sequencing data collected for this study, requests to access the raw sequencing dataset from qualified researchers trained in human subject confidentiality protocols may be sent to the corresponding author.

**Western blotting**

Protein extraction was mediated by RIPA lysis buffer (89901; Thermo Fisher Scientific) supplemented with phosphatase inhibitors (PhosSTOP; Roche) and protease inhibitors (cComplete; Roche). After determining protein concentrations with Pierce BCA protein assay kit (Thermo Fisher Scientific), proteins were reduced using NuPAGE reducing agent (Thermo Fisher Scientific) and NuPAGE LDS sample buffer (Thermo Fisher Scientific) and loaded on 4%–15% acrylamide Mini-Protein TGX gel (Bio-Rad). After running gel electrophoreses, proteins were transferred to a PVDF membrane and blocked in 5% BSA in Tris-buffered saline with Tween (TBST). Primary antibody used was anti-FSTL1 (1:1,000; MAB1694; R&D Systems), and detection was mediated by secondary anti-rat horseradish peroxidase (HRP)-conjugated antibody (1:2,000; 31470; Thermo Fisher Scientific) in a Bio-Rad ChemiDoc Imager system.

**Flow cytometry**

Cells were gently dissociated using the Multi Tissue Dissociation Kit (Miltenyi Biotec) and incubated using the LIVE/DEAD Fixable Green Dead cell stain kit (Thermo Fisher Scientific). Cells were fixed in inside fix solution (Miltenyi Biotec) and stained with primary antibodies diluted in inside perm solution (Miltenyi Biotec). Conjugated
primary antibodies used were α-actinin-VioBlue (1:10; 130-106-996; Miltenyi Biotec) and KI67-APC (1:10; 130-111-761; Miltenyi Biotec). As a control, universal isotype control antibodies (REA; Miltenyi Biotec) were used. Media and washes were collected to obtain a complete representation of cell loss. The samples were analyzed using the FACS Canto system (BD Bioscience) and FlowJo software.

Luminex bead-based array
Media were analyzed for FSTL1 protein levels using the Luminex magnetic bead-based multiplex array (R&D Systems) according to the manufacturer’s instructions. In short, a standard curve was generated using calibrator diluent, and the standards and samples were transferred to a microplate. The multiparticle cocktail was added to the wells, and the plate was incubated for 2 h at room temperature on a horizontal orbital microplate shaker, after which the plates were washed and consecutively incubated with the diluted Biotin-Antibody Cocktail and the diluted Streptavidin-PE cocktail. After resuspending the magnetic microparticles, the plates were read using a Luminex Analyzer (R&D Systems).

Statistical analysis
Experiments were performed on iPSC lines from two donors. The n value is depicted in the figures for the individual experiments and represents the number of independent experiments performed with cells yielded from separate differentiations. Statistical analysis was performed using Prism 8 (GraphPad Software), and quantifications are represented as mean ± SEM. To compare the expression of 2 groups, a normality test was performed followed by Student’s t test. For >2 groups, one-way ANOVA was used after confirmation of normal distribution using the Shapiro-Wilk test. Post hoc analysis was done using Dunnett multiple-comparisons tests to determine statistically significant (p < 0.05) results.

Study approval
Derivation and use of human iPSCs and human fetal cardiac progenitor cells or cFBs were approved by the ethics committee of University Medical Center Utrecht (Utrecht, the Netherlands). All subjects provided informed consent prior to participation.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.omtm.2022.02.005.

ACKNOWLEDGMENTS
We would like to gratefully acknowledge Michal Mokry for performing the RNA-seq library preparation and CEL-seq, Tomo Šarić and Joseph Wu for providing human iPSC lines, and Nino Chirico for providing iPSC-derived FBs. This work is supported by a Health Holland grant (DELICATE). M.C.P. is supported by a Netherlands Cardiovascular Research Initiative (CVON) grant (REMAIN 2014B27), and J.P.G.S. is supported by the PLN foundation and Horizon 2020 ERC-2016-COG-EVICARE 725229 and BRAVE (grant 874827).

AUTHOR CONTRIBUTIONS
J.P.G.S., S.A.J.C., P.A.D., K.N., and M.C.P. designed experiments. S.D.M., T.B., J.Q., and M.C.P. performed all experiments. M.C.P. analyzed data. M.C.P., A.M., and K.N. wrote the manuscript.

DECLARATION OF INTEREST
The authors declare no competing interests.

REFERENCES
1. Townsend, N., Wilson, L., Bhatnagar, P., Wickramasinghe, K., Rayner, M., and Nichols, M. (2016). Cardiovascular disease in europe: epidemiological update 2016. Eur. Heart J. 37, 3232–3245.
2. Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., Das, S.R., de Ferranti, S., Després, J.P., Fullerton, H.J., et al. (2016). Heart disease and stroke statistics — 2016 update a report from the American heart association. AHA Stat. Updat. 133, 38–360.
3. Jopling, C., Sleep, E., Raya, M., Marti, M., Raya, A., and Izpisua Belmonte, J.C. (2010). Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature 464, 606–609.
4. Porrello, E.R., Mahmoud, A.I., Simpson, E., Hill, J.A., Richardson, J.A., Olson, E.N., and Sadek, H.A. (2011). Transient regenerative potential of the neonatal mouse heart. Science 331, 1078–1081.
5. Engel, F.B. (2005). Cardiomyocyte proliferation: a platform for mammalian cardiac repair. Cell Cycle 4, 1360–1363.
6. Zhen, Y.S., Wu, Q., Xiao, C.L., Zhang, N.N., Wang, X., Lei, L., Zhu, X., and Xiong, J.W. (2012). Overlapping cardiac programs in heart development and regeneration. J. Genet. Genomics 39, 443–449.
7. Oerlemans, M.I.F.J., Goumans, M.J., Van Middelaar, B., Clevers, H., Doevendans, P.A., and Sluijter, J.P.G. (2010). Active Wnt signaling in response to cardiac injury. Basic Res. Cardiol. 105, 631–641.
8. Porrello, E.R., and Olson, E.N. (2014). A neonatal blueprint for cardiac regeneration. Stem Cell Res. 13, 556–570.
9. Olson, E.N., and Schneider, M.D. (2003). Sizing up the heart: development redux in disease. Genes Dev. 17, 1937–1956.
10. Poss, K.D. (2007). Getting to the heart of regeneration in zebrafish. Semin. Cell Dev Biol. 18, 36–45.
11. Kikuchi, K., Gupta, V., Wang, J., Holdway, J.E., Wills, A.A., Fang, Y., and Poss, K.D. (2011). Tcf21+ epicardial cells adopt non-myocardial fates during zebrafish heart development and regeneration. Development 138, 2895–2902.
12. Masters, M., and Riley, P.R. (2014). The epicardium signals the way towards heart regeneration. Stem Cell Res. 13, 683–692.
13. Schnabel, K., Wu, Y.C., Kurth, T., and Weidinger, G. (2018). Regeneration of cryoinjury induced necrotic heart lesions in zebrafish is associated with epicardial activation and cardiomyocyte proliferation. PLoS One 6, e18503.
14. Cao, J., and Poss, K.D. (2018). The epicardium as a hub for heart regeneration. Nat. Rev. Cardiol. 15, 631–647.
15. Marín-Juez, R., Marass, M., Gauvrit, S., Rossi, A., Lai, S.L., Materna, S.C., Black, B.L., and Stainier, D.Y. (2016). Fast revascularization of the injured area is essential to support zebrafish heart regeneration. Proc. Natl. Acad. Sci. U S A 113, 11237–11242.
16. Doroudgar, S., and Glombootski, C.G. (2011). The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart. Trends Mol. Med. 17, 207–214.
17. Perbellini, F., Watson, S.A., Bardi, I., and Terracciano, C.M. (2018). Heterocellularity and cellular cross-talk in the Cardiovascular system. Front Cardiovasc. Med. 5, 1–11.
18. Zhang, P., Su, J., and Mende, U. (2012). Cross talk between cardiac myocytes and fibroblasts: from multiscale investigative approaches to mechanisms and functional consequences. Am. J. Physiol. – Hear Circ. Physiol. 303, H1385–H1396.
19. Wu, Y.S., Zhu, B., Luo, A.L., Yang, L., and Yang, C. (2018). The role of cardiokines in heart diseases: beneficial or detrimental? Biomed. Res. Int. 2018, 8207658.
20. Wei, K., Serpooshan, V., Hurtado, C., Diez-Cuñado, M., Zhao, M., Maruyama, S., Zhu, W., Fajardo, G., Noseda, M., Nakamura, K., et al. (2015). Epicardial FSTL1 regeneration restores the adult mammalian heart. Nature 525, 479–485.

21. Shimano, M., Ouchi, N., Nakamura, K., van Wijk, B., Ohashi, K., Asaumi, Y., Higuchi, A., Pinetel, D.R., Sam, F., Murabora, T., et al. (2011). Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proc. Natl. Acad. Sci. U S A 108, 899–906.

22. Gögens, S.W., Raschke, S., Holven, K.B., Jensen, J., Eckardt, K., and Ecken, J. (2013). Regulation of follistatin-like protein 1 expression and secretion in primary human skeletal muscle cells. Arch. Physiol. Biochem. 119, 75–80.

23. Ogura, Y., Ouchi, N., Ohashi, K., Shibata, R., Katoa, Y., Kambara, T., Kito, T., Maruyama, Y., Yuasa, D., Matsuo, K., et al. (2012). Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation 126, 1728–1738.

24. Chiba, A., Watanabe-Takano, H., Miyazaki, T., and Mochizuki, N. (2018). Cardiomyocytes from the heart. Cell Mol Life Sci. 75, 1349–1362.

25. Xiao, Y., Zhang, Y., Chen, Y., Li, J., Zhang, Z., Sun, Y., Shen, H., Zhao, Z., Huang, Z., Zhang, W., et al. (2019). Inhibition of MicroRNA-9-5p protects against cardiac remodelling following myocardial infarction in mice. Hum. Gene Ther. 30, 286–301.

26. Ouchi, N., Oshima, Y., Ohashi, K., Higuchi, A., Ikegami, C., Izumiya, W., and Walsh, K. (2008). Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J. Biol. Chem. 283, 32802–32811.

27. Peters, M.M.C., Meij, T.A., Gathier, W., Doevendans, P.A.M., Sluijter, J.P.G., Chamuleau, S.A.J., and Neef, K. (2019). Follistatin-like 1 in Cardiovascular disease and inflammation. Mini-reviews Med. Chem. 19, 1379–1389.

28. Oshima, Y., Ouchi, N., Sato, K., Izumiya, Y., Pinetel, D.R., and Walsh, K. (2008). Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 117, 3099–3108.

29. Li, X., Li, L., Chang, Y., Ning, W., and Liu, X. (2019). Structural and functional study of FSTL1 reconstitutes the adult mammalian heart. Nature 525, 479–485.

30. Magadum, A., Singh, N., Kurian, A.A., Sharkar, M.T.K., Chepurko, E., and Zangi, L. (2011). Cardiomyocyte follistatin-like 1 decreases the angiotensin II-inducible hypertrophy in cardiac myocytes. Circ. Res. 115, E12245–E12254.

31. Maruyama, S., Yuasa, D., Matsuo, K., et al. (2012). Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation 126, 1728–1738.

32. Kretzschmar, K., Post, Y., Bannier-Hélaouët, M., Mattiotti, A., Drost, J., Basak, O., Li, K., Zwijsen, A., Block, H., Van Arnhem, W., Janssens, L., Devos, K., Raymackers, J., Van de Voorde, A., and Slegers, H. (1994). Characterization of a human homologue. Eur. J. Biochem. 225, 937–946.

33. Han, Y., Chen, A., Umansky, K.B., Oonk, K.A., Zhang, W., et al. (2012). The role of follistatin-like 1 in cardiac development and function. Circ. Res. 111, 1241–1249.

34. Diez-Cuñado, M., Wei, K., Bushway, P.I., Mauvy, M.R., Perera, R., Subramaniam, S., Ruiz-Lozano, P., Mercola, M., et al. (2018). miRNAs that induce human cardiomyocyte proliferation converge on the hippo pathway. Cell Res. 23, 2168–2174.

35. Heallen, T., Zhang, M., Wang, J., Bonilla-Claudio, M., Klysk, E., Johnson, R.L., and Martin, F.J. (2011). Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458–461.

36. D’Uva, G., Aharanov, A., Lauriola, M., Kain, D., Yahalom-Ronen, Y., Carvalho, S., Weisinger, K., Bassat, E., Rajchman, D., Yifa, O., et al. (2015). FBZB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat. Cell Biol. 17, 627–638.

37. Han, Y., Chen, A., Umansky, K.B., Oonk, K.A., Choi, W.Y., Dickson, A.L., Ou, J., Cigliola, V., Yifa, O., Cao, J., et al. (2019). Vitamin D stimulates cardiomyocyte proliferation and controls organelle size and regeneration in zebrafish. Dev. Cell 48, 853–863.e5.

38. Collesi, C., Felician, G., Secco, I., Gutierrez, M.I., Martelletti, E., Ali, H., Zentilin, L., Myers, M.P., and Giauca, R. (2018). Reversible Notch acetylation tunes proliferative signaling in cardiomyocytes. Cardiovasc. Res. 114, 103–122.

39. Zhao, L., Ben-Yair, R., Burns, C.E., and Burns, C.G. (2019). Endocardial Notch signaling promotes cardiomyocyte proliferation in the regenerating zebrafish heart through Wnt pathway antagonism. Cell Rep. 26, 546–554.e5.

40. Van Ojen, M.G.C.T., Medema, R.H., Slootweg, P.J., and Rijksen, G. (1998). Positive regulation of the proliferation marker Ki-67 in noncycling cells. Am. J. Clin. Pathol. 110, 24–31.

41. Sun, X., and Kaufman, P. (2018). Ki-67: more than a proliferation marker. Chromosoma 127, 175–186.

42. Zwijsen, A., Blockx, H., Van Arnhem, W., Willems, J., Fransen, L., Devos, K., Raymackers, J., Van de Voorde, A., and Slegers, H. (1994). Characterization of a rat C6 glioma-secreted follistatin-related protein (FRP): cloning and sequence of the human homologue. Eur. J. Biochem. 225, 937–946.

43. Han, Y., Chen, A., Umansky, K.B., Oonk, K.A., Zhang, W., et al. (2012). The role of follistatin-like 1 in cardiac development and function. Circ. Res. 111, 1241–1249.
59. El-Armouche, A., Ouchi, N., Tanaka, K., Doros, G., Wittköpper, K., Schulze, T., Eschenhagen, T., Walsh, K., and Sam, F. (2011). Follistatin-like 1 in chronic systolic heart failure a marker of left ventricular remodeling. Circ. Hear Fail 4, 621–627.

60. Widera, C., Horn Wichmann, R., Kempf, T., Bethmann, K., Fiedler, B., Sharma, S., Lichtinghagen, R., Leitolf, H., Ivanic, B., Katus, H.A., et al. (2009). Circulating concentrations of follistatin-like 1 in healthy individuals and patients with acute coronary syndrome as assessed by an immunoluminometric sandwich assay. Clin. Chem. 55, 1794–1800.

61. Meyer, B.A., and Doroudgar, S. (2020). ER stress-induced secretion of proteins and their extracellular functions in the heart. Cells 9, 1–17.

62. Mattiotti, A., Prakash, S., Barnett, P., and van den Hoff, M.J.B. (2018). Follistatin-like 1 in development and human diseases. Cell Mol Life Sci. 75, 2339–2354.

63. Ouchi, N., Asaumi, Y., Ohashi, K., Higuchi, A., Sono-Romanelli, S., Oshima, Y., and Walsh, K. (2010). DIP2A functions as a FSTL1 receptor. J. Biol. Chem. 285, 7127–7134.

64. Fang, D., Shi, X., Lu, T., Ruan, H., and Gao, Y. (2019). The glycoprotein follistatin-like 1 promotes brown adipose thermogenesis. Metabolism 98, 16–26.

65. Van Den Berg, G., Somi, S., Buffing, A.A.M., Moorman, A.F.M., and van den Hoff, M.J.B. (2007). Patterns of expression of the follistatin and follistatin-like1 genes during chicken heart development: a potential role in valvulogenesis and late heart muscle cell formation. Anat. Rec. 290, 783–787.

66. Seki, M., Powers, J.C., Maruyama, S., Zuriaga, M.A., Wu, C.L., Kurishima, C., Kim, L., Johnson, J., Poidomani, A., Wang, T., et al. (2018). Acute and chronic increases of circulating FSTL1 normalize energy substrate metabolism in pacing-induced heart failure. Circ. Hear Fail. 11, 1–12.

67. Schotman, M.J.G., Peters, M.M.C., Krüger, G.C., Van Adrichem, I., de Roos, R., Benelmans, J.L.M., Poudroijen, M.J., Rutten, M.G.T.A., Neel, K., Chamuleau, S.A.J., et al. (2021). In Vivo retention quantification of supramolecular hydrogels engineered for cardiac delivery. Adv Healthc Mater. 10, e2001987.

68. Speed, J.S., and Hyndman, K.A. (2016). In vivo organ specific drug delivery with implantable peristaltic pumps. Sci. Rep. 6, 1–7.

69. Spannbauer, A., Mester-tonczar, J., Traxler, D., Kastner, N., Zlabinger, K., Haisimbegović, E., Riesenhuber, M., Pavo, N., Golasch, G., and Gyöngyösi, M. (2020). Large animal models of cell-free cardiac regeneration. Biomolecules 10, 1–19.

70. Matsa, E., Burridge, P.W., Yu, K.H., Ahrens, J.H., Termgl镀锌han, V., Wu, H., Liu, C., Shukla, P., Sayed, N., Churko, J.M., Shao, N., et al. (2016). Transcriptome profiling of patient-specific human iPSC-cardiomyocytes predicts individual drug safety and efficacy responses in vitro. Cell Stem Cell 19, 311–325.

71. Hamad, S., Derichsweiler, D., Papadopoulos, S., Nguemo, F., Šaric, T., Sachindis, A., Brockmeier, K., Hescheler, J., Boukens, B.I., and Pfannkuche, K. (2019). Generation of human induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer and scalable 3D suspension bioreactor cultures with reduced batch-to-batch variations. Theranostics 9, 7222–7238.

72. Zhang, J., Tao, R., Campbell, K.F., Carvalho, J.L., Ruiz, E.C., Kim, G.C., Schmuck, E.G., Raval, A.N., da Rocha, A.M., Herron, T.J., et al. (2019). Functional cardiac fibroblasts derived from human pluripotent stem cells via second heart field progenitors. Nat. Commun. 10, 2238.

73. Bracco Gartner, T.C.L., Deddens, J.C., Mol, E.A., Magin Ferrer, M., van Laake, L.W., Bonten, C.V.C., Khademhosseini, A., Doevendans, P.A., Suyker, W.J.L., Sluijter, J.P.G., et al. (2019). Anti-fibrotic effects of cardiac progenitor cells in a 3D-model of human cardiac fibrosis. Front Cardiovasc. Med. 6, 1–11.

74. Afgan, E., Baker, D., Batut, B., van den Beek, M., Bouvier, D., Cech, M., Chilton, J., Clements, D., Coraor, N., and Grünig, B.A. (2018). The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 46, W537–W544.